341 related articles for article (PubMed ID: 26379820)
1. Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin.
Refaat B; El-Shemi AG; Ashshi A; Azhar E
Int J Clin Exp Med; 2015; 8(7):10284-303. PubMed ID: 26379820
[TBL] [Abstract][Full Text] [Related]
2. [Clinical observation of Hashimoto thyroiditis in patients with chronic hepatitis C undergoing pegylated-interferon alpha-2a and ribavirin combination therapy].
Teng ZL; Gong WJ; Zhang SQ; Sun YX; Ma XH
Zhonghua Gan Zang Bing Za Zhi; 2013 Feb; 21(2):101-4. PubMed ID: 23663880
[TBL] [Abstract][Full Text] [Related]
3. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial.
Yokoyama S; Takahashi S; Kawakami Y; Hayes CN; Kohno H; Kohno H; Tsuji K; Aisaka Y; Kira S; Yamashina K; Nonaka M; Moriya T; Kitamoto M; Aimitsu S; Nakanishi T; Kawakami H; Chayama K
J Viral Hepat; 2014 May; 21(5):348-56. PubMed ID: 24716637
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C].
Feng B; Shang J; Wu SH; Chen H; Han Y; Li YQ; Zhang DZ; Zhao LF; Wei SF; Mao Q; Yin CB; Han T; Wang MR; Chen SJ; Li J; Xie Q; Zhen Z; Gao ZL; Zhang YX; Gong GZ; Yang DL; Pan C; Sheng JF; Tang H; Ning Q; Shi GF; Niu JQ; Luo GH; Sun YT; You H; Wang GQ; Zhang LL; Peng J; Zhang Q; Liu JJ; Chen CW; Chen XY; Zhao W; Wang RH; Sun L; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):187-194. PubMed ID: 28482405
[No Abstract] [Full Text] [Related]
5. Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus.
Foster GR
Expert Opin Pharmacother; 2003 May; 4(5):685-91. PubMed ID: 12739994
[TBL] [Abstract][Full Text] [Related]
6. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin.
Esmat G; El Raziky M; Elsharkawy A; Sabry D; Hassany M; Ahmed A; Assem N; El Kassas M; Doss W
J Interferon Cytokine Res; 2015 Jan; 35(1):49-54. PubMed ID: 25061714
[TBL] [Abstract][Full Text] [Related]
7. Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.
Hwang Y; Kim W; Kwon SY; Yu HM; Kim JH; Choe WH
Korean J Intern Med; 2015 Nov; 30(6):792-800. PubMed ID: 26552454
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C in patients with congenital coagulation disorders.
Katsarou O; Theodosiades G; Ioannidou P; Nomikou E; Tsevrenis B; Kouraba A; Deutch M; Terpos E; Dourakis S; Karafoulidou A
Acta Haematol; 2008; 120(2):63-9. PubMed ID: 18827474
[TBL] [Abstract][Full Text] [Related]
9. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
Rustgi VK; Lee WM; Lawitz E; Gordon SC; Afdhal N; Poordad F; Bonkovsky HL; Bengtsson L; Chandorkar G; Harding M; McNair L; Aalyson M; Alam J; Kauffman R; Gharakhanian S; McHutchison JG;
Hepatology; 2009 Dec; 50(6):1719-26. PubMed ID: 19852040
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha induced and ribavirin induced thyroid dysfunction in patients with chronic hepatitis C.
Nadeem A; Hussain MM; Aslam M; Hussain T
Hepat Mon; 2010; 10(2):132-40. PubMed ID: 22312386
[TBL] [Abstract][Full Text] [Related]
11. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
12. Transient Hypothyroidism and Autoimmune Thyroiditis in Children With Chronic Hepatitis C Treated With Pegylated-interferon-α-2b and Ribavirin.
Serranti D; Indolfi G; Nebbia G; Cananzi M; D'Antiga L; Ricci S; Stagi S; Azzari C; Resti M;
Pediatr Infect Dis J; 2018 Apr; 37(4):287-291. PubMed ID: 28953189
[TBL] [Abstract][Full Text] [Related]
13. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
[TBL] [Abstract][Full Text] [Related]
14. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Hunyady B; Kovács B; Battyáni Z
Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
[TBL] [Abstract][Full Text] [Related]
15. HLA-B*15:02 is associated with anemia in patients with chronic hepatitis C treated with pegylated interferon-α and ribavirin.
Tseng CW; Hsieh YH; Chang CK; Lai NS; Hung TH; Wu SF; Tseng KC
Tissue Antigens; 2012 Nov; 80(5):424-30. PubMed ID: 22931407
[TBL] [Abstract][Full Text] [Related]
16. [Extrahepatic manifestations of chronic hepatitis C and their influence on response to treatment with pegylated interferon alfa-2a and ribavirin].
Fabri M; Ruzić M; Lendak D; Preveden T; Fabri I; Petrić V
Srp Arh Celok Lek; 2013; 141(5-6):320-4. PubMed ID: 23858800
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan.
Chang YK; Tseng YT; Chen KH; Chen KT
BMC Endocr Disord; 2019 Apr; 19(1):36. PubMed ID: 30953492
[TBL] [Abstract][Full Text] [Related]
18. Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C.
Rashed YK; Khalaf FA; Kotb SE
Clin Exp Pediatr; 2020 Feb; 63(2):52-55. PubMed ID: 32024338
[TBL] [Abstract][Full Text] [Related]
19. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism.
Carella C; Mazziotti G; Morisco F; Rotondi M; Cioffi M; Tuccillo C; Sorvillo F; Caporaso N; Amato G
Eur J Endocrinol; 2002 Jun; 146(6):743-9. PubMed ID: 12039693
[TBL] [Abstract][Full Text] [Related]
20. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
